Correlation Between Prime Medicine, and Adaptive Biotechnologies

Can any of the company-specific risk be diversified away by investing in both Prime Medicine, and Adaptive Biotechnologies at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Prime Medicine, and Adaptive Biotechnologies into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Prime Medicine, Common and Adaptive Biotechnologies Corp, you can compare the effects of market volatilities on Prime Medicine, and Adaptive Biotechnologies and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Prime Medicine, with a short position of Adaptive Biotechnologies. Check out your portfolio center. Please also check ongoing floating volatility patterns of Prime Medicine, and Adaptive Biotechnologies.

Diversification Opportunities for Prime Medicine, and Adaptive Biotechnologies

-0.27

Correlation Coefficient

Prime Medicine,  Adaptive Biotechnologies

Very good diversification

The 3 months correlation between Prime and Adaptive is -0.27. Overlapping area represents the amount of risk that can be diversified away by holding Prime Medicine, Common and Adaptive Biotechnologies Corp in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Adaptive Biotechnologies and Prime Medicine, is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Prime Medicine, Common are associated (or correlated) with Adaptive Biotechnologies. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Adaptive Biotechnologies has no effect on the direction of Prime Medicine, i.e., Prime Medicine, and Adaptive Biotechnologies go up and down completely randomly.

Pair Corralation between Prime Medicine, and Adaptive Biotechnologies

Given the investment horizon of 90 days Prime Medicine, Common is expected to under-perform the Adaptive Biotechnologies. In addition to that, Prime Medicine, is 1.09 times more volatile than Adaptive Biotechnologies Corp. It trades about -0.07 of its total potential returns per unit of risk. Adaptive Biotechnologies Corp is currently generating about 0.12 per unit of volatility. If you would invest  611.00  in Adaptive Biotechnologies Corp on December 29, 2024 and sell it today you would earn a total of  211.00  from holding Adaptive Biotechnologies Corp or generate 34.53% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

Prime Medicine, Common  vs.  Adaptive Biotechnologies Corp

Prime Medicine, Common

Risk-Adjusted Performance

Very Weak

Over the last 90 days Prime Medicine, Common has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Etf's primary indicators remain rather sound which may send shares a bit higher in April 2025. The latest tumult may also be a sign of longer-term up-swing for the fund shareholders.

Adaptive Biotechnologies

Risk-Adjusted Performance

OK

Compared to the overall equity markets, risk-adjusted returns on investments in Adaptive Biotechnologies Corp are ranked lower than 9 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively abnormal basic indicators, Adaptive Biotechnologies unveiled solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Prime Medicine, and Adaptive Biotechnologies

The main advantage of trading using opposite Prime Medicine, and Adaptive Biotechnologies positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Prime Medicine, position performs unexpectedly, Adaptive Biotechnologies can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Adaptive Biotechnologies will offset losses from the drop in Adaptive Biotechnologies' long position.

The idea behind Prime Medicine, Common and Adaptive Biotechnologies Corp pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.